辅助治疗。
Adjuvant treatment.
机构信息
Division of Surgery and Oncology, University of Liverpool, Liverpool, UK.
出版信息
HPB (Oxford). 2006;8(5):352-64. doi: 10.1080/13651820600804146.
Exocrine pancreatic cancer (pancreatic ductal adenocarcinoma) is one of the leading causes of cancer deaths in the western world, accounting for 5% of all cancer-related deaths. Only a small percentage of patients with pancreatic cancer are able to undergo potentially curative resection, even in specialized centres, and prognosis remains poor after successful surgery. Over the last few years efforts have been directed towards the development of adjuvant therapies in attempts to improve outcome. The main trials of adjuvant chemotherapy, chemoradiotherapy and chemoradiotherapy with follow-on chemotherapy are described in this paper, followed by the results of the ESPAC-1 trial and the status of ESPAC-2 and -3 trials.
外分泌胰腺肿瘤（胰腺导管腺癌）是西方世界主要的癌症死因之一，占所有癌症相关死亡人数的 5%。即使在专业中心，也只有一小部分胰腺癌患者能够接受潜在的治愈性切除，而且手术后的预后仍然很差。在过去的几年中，人们一直在努力开发辅助治疗方法，试图改善治疗效果。本文描述了辅助化疗、放化疗和放化疗后辅助化疗的主要试验，接着介绍了 ESPAC-1 试验的结果以及 ESPAC-2 和 -3 试验的现状。
Zotero 插件